Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine

The Breast : Official Journal of the European Society of Mastology
Giuseppe CuriglianoA Goldhirsch

Abstract

To assess efficacy of bevacizumab in combination with oral chemotherapy in patients with breast cancer with lymphangitic spread to the chest wall (LBC). To identify surrogate biomarkers of response to bevacizumab. We randomly assigned patients to receive bevacizumab plus either sequential or concurrent oral vinorelbine and capecitabine every 3 weeks. The primary endpoint was time to ultimate progression (TTP); the response rate and overall survival (OS) were secondary endpoints. We performed gene expression profiling on baseline tissue samples collected from triple negative LBC. We assessed circulating endothelial cells (CEC), circulating endothelial progenitors (CEP) and circulating pericyte progenitors (CPP). A total of 66 patients were enrolled. There was no difference in TTP (median TTP 5.3 vs. 4.8 months, p = 0.21) and in OS (median OS 15.8 vs 11.9 months; p = 0.25) when comparing concurrent vs sequential treatment, respectively. Response rate was 25% vs 28% in the concurrent vs sequential arm (p = 1.00), respectively. A set of 16 genes predictive of response to bevacizumab was identified. The counts of CEPs and viable CECs below the median value were associated with an improved overall survival: 26.6 vs 9.5 months for CEP...Continue Reading

References

Aug 6, 2004·Endocrine Reviews·Napoleone Ferrara
Nov 10, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ilse Van der AuweraPeter B Vermeulen
Jan 5, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suparna Bonthala WedamSandra M Swain
Oct 13, 2006·Nature Reviews. Cancer·Francesco BertoliniRobert S Kerbel
Oct 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Beth OvermoyerScot C Remick
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert GrayRobert L Comis
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David W MilesGilles Romieu
Jan 27, 2012·The New England Journal of Medicine·Gunter von MinckwitzUNKNOWN Arbeitsgemeinschaft Gynäkologische Onkologie–Breast Study Groups
Jan 27, 2012·The New England Journal of Medicine·Harry D BearNorman Wolmark
Apr 10, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca GianniVladimir Semiglazov
May 7, 2013·The Breast : Official Journal of the European Society of Mastology·Matteo ClavarezzaLucia Del Mastro
Dec 5, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F BertucciS J Van Laere
Mar 29, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S DawoodA M Gonzalez-Angulo

❮ Previous
Next ❯

Citations

Apr 10, 2021·Cellular Oncology (Dordrecht)·Jamal Majidpoor, Keywan Mortezaee

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.